Literature DB >> 19571677

Lipocalin 2: a multifaceted modulator of human cancer.

Jiang Yang1, Marsha A Moses.   

Abstract

Lipocalin 2 (Lcn2), a member of the lipocalin family that transports small lipophilic ligands, has gained recent attention as both a potential biomarker and a modulator of human cancers. Here we describe recent findings of the functions of Lcn2 in breast cancer and the potential mechanisms that underlie its actions. Lcn2 has been shown to induce the epithelial to mesenchymal transition (EMT) in breast cancer cells and to promote breast tumor invasion. Estrogen receptor alpha may participate in the pathway that leads to Lcn2-induced EMT. Preliminary evidence also suggests that Lcn2 may be useful as a potential non-invasive urinary biomarker of breast cancer. Elevated levels of Lcn2 have also been reported in other human cancers. The potential roles of Lcn2 in epithelial tumors as well as leukemia are also reviewed and discussed here.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19571677      PMCID: PMC3381736          DOI: 10.4161/cc.8.15.9224

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  58 in total

1.  A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake.

Authors:  Laxminarayana R Devireddy; Claude Gazin; Xiaochun Zhu; Michael R Green
Journal:  Cell       Date:  2005-12-29       Impact factor: 41.582

Review 2.  Complex networks orchestrate epithelial-mesenchymal transitions.

Authors:  Jean Paul Thiery; Jonathan P Sleeman
Journal:  Nat Rev Mol Cell Biol       Date:  2006-02       Impact factor: 94.444

3.  Proteomics-based validation of genomic data: applications in colorectal cancer diagnosis.

Authors:  Juan Madoz-Gúrpide; Paula López-Serra; Jorge Luis Martínez-Torrecuadrada; Lydia Sánchez; Luis Lombardía; J Ignacio Casal
Journal:  Mol Cell Proteomics       Date:  2006-05-29       Impact factor: 5.911

4.  Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells.

Authors:  Ho-Jeong Lee; Eun-Kyoung Lee; Kong-Ju Lee; Soon-Won Hong; Yeup Yoon; Jang-Seong Kim
Journal:  Int J Cancer       Date:  2006-05-15       Impact factor: 7.396

5.  Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition.

Authors:  Ratana Lim; Nuzhat Ahmed; Niels Borregaard; Clyde Riley; Razan Wafai; Erik W Thompson; Michael A Quinn; Gregory E Rice
Journal:  Int J Cancer       Date:  2007-06-01       Impact factor: 7.396

6.  Neutrophil gelatinase-associated lipocalin as a survival factor.

Authors:  Zhimin Tong; Xuli Wu; Dmitriy Ovcharenko; Jiuxiang Zhu; Ching-Shih Chen; James P Kehrer
Journal:  Biochem J       Date:  2005-10-15       Impact factor: 3.857

7.  Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer.

Authors:  Maret Bauer; Jens C Eickhoff; Michael N Gould; Christoph Mundhenke; Nicolai Maass; Andreas Friedl
Journal:  Breast Cancer Res Treat       Date:  2007-06-07       Impact factor: 4.872

8.  Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells.

Authors:  Sharon J Pitteri; Vitor M Faca; Karen S Kelly-Spratt; A Erik Kasarda; Hong Wang; Qing Zhang; Lisa Newcomb; Alexei Krasnoselsky; Sophie Paczesny; Gina Choi; Matthew Fitzgibbon; Martin W McIntosh; Christopher J Kemp; Samir M Hanash
Journal:  J Proteome Res       Date:  2008-02-27       Impact factor: 4.466

9.  Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells.

Authors:  Amanda M Nelson; Wei Zhao; Kathryn L Gilliland; Andrea L Zaenglein; Wenlei Liu; Diane M Thiboutot
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

10.  Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion.

Authors:  Haihua Zhang; Liyan Xu; Dawei Xiao; Jianjun Xie; Hongmei Zeng; Zhaoyang Wang; Xiaoling Zhang; Yongdong Niu; Zhongying Shen; Jinghui Shen; Xuan Wu; Enmin Li
Journal:  J Clin Pathol       Date:  2007-04-05       Impact factor: 3.411

View more
  51 in total

1.  Lipocalin 2 is essential for chronic kidney disease progression in mice and humans.

Authors:  Amandine Viau; Khalil El Karoui; Denise Laouari; Martine Burtin; Clément Nguyen; Kiyoshi Mori; Evangéline Pillebout; Thorsten Berger; Tak Wah Mak; Bertrand Knebelmann; Gérard Friedlander; Jonathan Barasch; Fabiola Terzi
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

2.  Lipocalin-2 deficiency attenuates neuroinflammation and brain injury after transient middle cerebral artery occlusion in mice.

Authors:  Myungwon Jin; Jong-Heon Kim; Eunha Jang; Young Mi Lee; Hyung Soo Han; Dong Kyun Woo; Dong Ho Park; Hyun Kook; Kyoungho Suk
Journal:  J Cereb Blood Flow Metab       Date:  2014-04-30       Impact factor: 6.200

3.  Extended exposure to dietary melatonin reduces tumor number and size in aged male mice.

Authors:  Edward H Sharman; Kaizhi G Sharman; Stephen C Bondy
Journal:  Exp Gerontol       Date:  2010-09-16       Impact factor: 4.032

4.  Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel.

Authors:  Peng Guo; Jiang Yang; Jing Huang; Debra T Auguste; Marsha A Moses
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-26       Impact factor: 11.205

5.  Enhancement of ionizing radiation response by histamine in vitro and in vivo in human breast cancer.

Authors:  Diego J Martinel Lamas; Jorge E Cortina; Clara Ventura; Helena A Sterle; Eduardo Valli; Karina B Balestrasse; Horacio Blanco; Graciela A Cremaschi; Elena S Rivera; Vanina A Medina
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

6.  Lipocalin-2 is associated with a good prognosis and reversing epithelial-to-mesenchymal transition in pancreatic cancer.

Authors:  Bin Xu; Da-Yong Jin; Wen-Hui Lou; Dan-Song Wang
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

7.  Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.

Authors:  William H Chappell; Stephen L Abrams; Richard A Franklin; Michelle M LaHair; Giuseppe Montalto; Melchiorre Cervello; Alberto M Martelli; Ferdinando Nicoletti; Saverio Candido; Massimo Libra; Jerry Polesel; Renato Talamini; Michele Milella; Agostino Tafuri; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2012-11-16       Impact factor: 4.534

8.  Prospects for treating osteoarthritis: enzyme-protein interactions regulating matrix metalloproteinase activity.

Authors:  Evan Meszaros; Charles J Malemud
Journal:  Ther Adv Chronic Dis       Date:  2012-09       Impact factor: 5.091

9.  The Ligands of Neutrophil Gelatinase-Associated Lipocalin.

Authors:  Guan-Hu Bao; Chi-Tang Ho; Jonathan Barasch
Journal:  RSC Adv       Date:  2015-12-03       Impact factor: 3.361

10.  Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.

Authors:  Jiang Yang; Brendan McNeish; Catherine Butterfield; Marsha A Moses
Journal:  FASEB J       Date:  2012-09-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.